Veracyte Named a San Francisco Bay Area "Top Workplace" For Fourth Consecutive Year

SOUTH SAN FRANCISCO, Calif., June 26, 2017

"We are honored and humbled to receive this award and grateful to our employees for their strong enthusiasm and support for Veracyte," said Bonnie Anderson, Veracyte's chairman and chief executive officer. "We are passionate about improving patient care with our genomic tests and believe we have built a culture that reflects this passion, which is key to fueling our continued success."

The Top Workplaces award winners are determined by results of an employee feedback survey administered by WorkplaceDynamics, LLC, a leading research firm that specializes in organizational health and workplace improvement. Several key aspects of workplace culture were measured for the award, including organizational alignment, effective execution and meaningful connection with employees.

The Bay Area News Group published the complete list of 2017 Top Workplaces on Sunday, June 25. The list of winners is available at the Bay Area News Group website.

Veracyte's corporate and industry leadership has been recognized consistently over the past several years. In 2016, the company received the prestigious Edison Award honoring excellence in new product and service development, marketing, human-centered design and innovation. Ms. Anderson has also been named to Fast Company's 2015 list of the "100 Most Creative People in Business" and was named by the San Francisco Business Times in 2015 as one of the "Bay Area's Most Admired CEOs."

About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@Veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.